At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Ramelteon +1 moredrug
Likely dose
Ramelteon 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
In Brief
A Phase 4 clinical trial evaluating Ramelteon and Placebo for Seasonal Affective Disorder. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether treating sleep difficulties in patients with seasonal affective disorder also improves their depressive symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Affective Disorder
CountriesUnited States
CollaboratorsTakeda Pharmaceuticals North America, Inc.
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedJul 2007
Primary CompletionApr 2008
Study CompletionJul 2008
TodayJul 2026
First PostedJul 17, 2007
Enrollment StartSep 1, 2006
Primary CompletionApr 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.0 years ago
Interventions
Ramelteondrug
one 8 mg tablet at bed for up to 4 months
Placebodrug
one tablet at bedtime for up to 4 months